Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.05 CAD | -5.28% | +4.10% | +177.27% |
May. 14 | Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure | MT |
Apr. 22 | HC Wainwright Starts Cardiol Therapeutics With Buy Rating, $9 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+177.27% | 161M | |
+33.04% | 50.85B | |
+0.31% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.73% | 26.11B | |
-22.15% | 19.13B | |
+8.64% | 13.05B | |
+27.07% | 12.16B | |
+24.43% | 12.08B |
- Stock Market
- Equities
- CRDL Stock
- News Cardiol Therapeutics Inc.
- Canaccord Genuity Adjusts Price Target on Cardiol Therapeutics to $6 From $5, Maintains Buy Rating